Longer follow-up is valuable, but an extension study does not preserve every advantage of its randomized parent trial. Primary report
Study snapshot
Women completing RECONNECT without a serious adverse event could enter a 52-week open-label extension. Of 856 eligible participants, 684 entered and 272 completed it. Analyses were descriptive. The report described maintained symptom improvements and no newly identified safety signal; nausea, flushing, and headache remained common treatment-related events. Primary report
Our appraisal: follow the selection process
There are several populations here: original trial entrants, eligible completers, people choosing the extension, and people finishing it. Each step can change the mix of participants. Those who tolerate or value treatment may be more willing to continue than those who do not.
That does not make the extension useless. It can add information about longer exposure, repeated events, and reasons for discontinuation. It does mean that the experience of remaining participants cannot automatically represent everyone who might start treatment.
Without a continuing blinded placebo comparison, maintained symptom scores do not establish the size of a long-term causal effect. Expectations, changes in other care, and selective observation remain possible contributors. Likewise, “no new signal” means no additional pattern was detected in the observed data, not that no harms occurred.
Review should preserve reasons and timing of withdrawal rather than treating every missing observation identically. Safety denominators should reflect actual exposure and follow-up. This paper extends the RECONNECT evidence record; it should not be counted as an independent randomized replication of the core trials.
Frequently asked questions
Was the extension blinded and placebo controlled?
No. It was open label.
Did every eligible participant enroll?
No. Entry was elective.
Did most entrants complete the full extension?
The reported completion count was 272 of 684 entrants.
Does no new signal mean no adverse events?
No. Adverse events were reported.
Why do withdrawal reasons matter?
They help assess whether missing follow-up is related to benefit or harm.
Is this an independent randomized confirmation?
No. It follows selected participants from the parent program.
What evidence does it add?
Longer observed treatment experience, subject to selection and missing-data limitations.